Distributor Settles Aussie Thalidomide Suit, Maker To Fight Alone
This article was originally published in PharmAsia News
Diageo, a UK drug distributor, settled an Australian thalidomide suit for several million dollars, but German drug maker Grunenthal, also a defendant, said it would continue to fight a class action suit.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.